ArticleScientific reports2025
Multi-omics analysis identifies novels genes involved in glioma prognosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Transcriptomic Evidence Identifies Two TMBIM Subgroups with Opposing Prognostic Associations in Glioma.Biology · 2026Article
- Review
- From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.International journal of molecular sciences · 2026Review
- Cancer Neuroscience: Linking Neuronal Plasticity with Brain Tumor Growth and Resistance.Biology · 2026Review
- Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives.International journal of molecular sciences · 2025Review
- Expression profile and prognostic relevance of immune infiltration-related RBMS1 in gliomas: a multidimensional integrative analysis.Journal of cancer research and clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Gliomas have highly variable clinical outcomes that are not adequately predicted on the basis of histologic class nor genetic markers. We performed a comprehensive analysis that integrated multi-omics datasets to elucidate factors influencing glioma prognosis. We detected 17 grade-related genes different in expression between LGG and GBM cohorts. By combining multi-layer information including genetic markers, DNA methylation and gene expression, we constructed two gene networks of relations from the grade-related genes. From the networks, we identified 178 prognostic genes whose activity states, in terms of DNA methylation and gene expression level, are relevant to prognostic outcomes of gliomas, with low activity associated with better outcomes. The efficacy of these 178 genes' activity states as prognostic factors beyond genetic markers, i.e. IDH1 or PTEN gene mutations, was validated externally. Among the 178 prognostic genes, we validated roles in gliomas for 121 genes from previous literature, and more importantly, we identified 67 novel candidate genes for glioma research. Expression of these 178 genes was particularly pronounced during fetal development in various brain regions. Our findings provide clues for understanding glioma prognosis and highlight some novel glioma-associated genes that warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.